Patents Examined by Rebecca Cook
  • Patent number: 7005429
    Abstract: This invention provides a method of treating estrogen receptor positive carcinoma in a mammal in need thereof which comprises administering an antineoplastic amount of 17(?-dihydroequilin or a mammalian metabolic conjugate thereof orally, parenterally, transdermally, topically, rectally, intravaginally, intranasally, or intrabronchially. As such, the compounds of this invention are useful in treating estrogen receptor positive carcinomas such as carcinomas of the breast, uterus, ovary, fallopian tube, cervix, vagina, liver, pituitary, central nervous system, hypothalamus, bone, skin, kidney, urethra, prostate, and the like.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: February 28, 2006
    Assignee: Wyeth
    Inventors: Michael S. Dey, Frederick J. Bex, Alan Corbin
  • Patent number: 6998404
    Abstract: Adenosine receptor antagonists, especially aminophyllline, are used to treat or prevent acute renal failure. In the preferred embodiment, aminophylline is administered by infusion so that it does not exceed a serum theophylline level of 15-20 micrograms/ml, most preferably the aminophylline is administered to achieve a serum theophylline concentration of 3-10 micrograms/ml, with an infusion rate of 0.1-0.6 mg/kg IBW/hour (IBW=ideal body weight). The adenosine receptor antagonist can also be used to help sustain a kidney for transplant purposes. Preferably, aminophylline is loaded while the kidney is still part of the donor. A dose of aminophylline of 5 mg/kg lean body weight is infused into the donor over a 30-60 min period, with cardiac monitoring. The infusion dose is decreased in the event of supraventricular or ventricular tachycardias. The kidney is removed and placed in the standard “cold” bath, but containing aminophylline at a dose of 5-10 micrograms/ml (5-10 mg/l).
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: February 14, 2006
    Assignee: GenoMed, LLC
    Inventor: David W. Moskowitz
  • Patent number: 6995173
    Abstract: Methods and compositions for treating specific patient groups for Central Nervous System disorders, including but not limited to Tourette Syndrome, are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives thereof) in patients with symptoms of a Central Nervous System Disorder who are otherwise free of cardiac disease and/or who have not been given organic nitrates.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: February 7, 2006
    Assignee: R.T. Alamo Ventures I, LLC
    Inventors: Neal R. Cutler, John Sramek
  • Patent number: 6992110
    Abstract: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: January 31, 2006
    Assignee: Cypress Bioscience, Inc.
    Inventors: Jay D. Kranzler, Srinivas G. Rao
  • Patent number: 6989383
    Abstract: The present invention relates to methods of treating cancer using a combination of a compound which is an antineoplastic agent and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at lest two therapeutic agents selected from a group consisting of a compound which is an antineoplastic agent and a compound which is an inhibitor or prenyl-protein transferase. The invention also relates to methods of preparing such compositions.
    Type: Grant
    Filed: June 4, 1998
    Date of Patent: January 24, 2006
    Assignee: Sloan-Kettering Institute For Cancer Research
    Inventors: Neal Rosen, Laura Sepp-Lorenzino, Mark M. Moasser, Allen I. Oliff, Jackson B. Gibbs, Nancy Kohl, Samuel L. Graham, George C. Prendergast
  • Patent number: 6984654
    Abstract: A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals and can be used to treat viral infections that comprises a fungicide is disclosed. The particular fungicide used is a benzimidazole derivative having the formula: wherein R is selected from the group consisting of H, carboxyl (—CO2H), hydroxyl, amino or esters (—CO2R?) wherein R? is selected from the group consisting of alkoxy, haloalkyl, alkenyl, and cycloalkyl wherein the alkyl groups have from 1–8 carbons or CH3CH2(OCH2CH2)n— or CH3CH2CH2(OCH2CH2CH2)n— or (CH3)2CH—(OCH(CH3)CH2)n— wherein n is from 1–3, the pharmaceutically acceptable salts thereof, or mixtures thereof.
    Type: Grant
    Filed: January 13, 2003
    Date of Patent: January 10, 2006
    Assignee: UAF Technologies and Research, LLC
    Inventor: James Berger Camden
  • Patent number: 6982284
    Abstract: The topical use of ursolic acid compounds to alter the lipid content of mammalian skin is disclosed. The compounds can be encapsulated in liposomes and administered in this form to the skin in, for example, a lotion or a gel. The compounds are effective in, among other things, reducing the effects of aging, photoaging, and skin atrophy, including skin atrophy resulting from the topical use of retinoids and/or steroids. Compositions comprising a ursolic acid compound in combination with another therapeutically active topical compounds, such as, a retinoid or a steroid, are also disclosed.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: January 3, 2006
    Assignee: Applied Genetics Incorporated Dermatics
    Inventors: David A. Brown, Daniel B. Yarosh
  • Patent number: 6979689
    Abstract: A composition of an antitussive, a decongestant, and diphenhydramine as an antihistamine to treat upper respiratory and oral pharyngeal congestion and related symptoms in a patient. In addition to providing antihistamine effects, diphenhydramine also provides effects as an anti-cholinergic, an analgesic, an antitussive, and an analgesic adjuvant.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: December 27, 2005
    Assignee: PediaMed Pharmaceuticals, Inc.
    Inventors: Gilbert R. Gonzales, Thomas P. Jennings, Norman D. Schellenger
  • Patent number: 6977269
    Abstract: A novel method for improving the tissue quality of an animal is provided. The method comprises feeding the animal a diet supplemented with gamma-tocopherol in an amount effective to improve the tissue quality. The gamma-tocopherol may be fed alone or in combination with other antioxidants, such as alpha-tocopherol. The method may be practiced on ruminants and non-ruminants.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: December 20, 2005
    Assignee: Pioneer Hi-Bred International, Inc
    Inventors: Court A. Saunders, Fred R. Wolf, Thomas E. Sauber, Fredric N. Owens
  • Patent number: 6977268
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: December 20, 2005
    Assignee: Children's Medical Center Corporation
    Inventor: Robert D'Amato
  • Patent number: 6977251
    Abstract: The instant application provides means of accelerating cell aging and programed cell death in tumor cells by administration of 3?,17? androstenediol (?AED) or its ethers or esters.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: December 20, 2005
    Inventor: Roger M. Loria
  • Patent number: 6967207
    Abstract: The compound of the following formula: wherein R1 and R2 independently represent a hydrogen atom or a lower alkyl group; A represents a group selected from the group consisting of 1-azabicyclo[3.2.2]nonyl group, 1-azabicyclo[2.2.2]octyl group, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof or a hydrate thereof has both improving effect on enterokinetic functions and suppressing effect on acid secretion, and also is highly safe. Accordingly, the substance is useful as preventive or therapeutic medicament for a gastroesophageal reflux disease.
    Type: Grant
    Filed: February 7, 2001
    Date of Patent: November 22, 2005
    Assignee: Mitsubishi Pharma Corporation
    Inventor: Satoshi Yamazaki
  • Patent number: 6960596
    Abstract: The present invention relates to therapeutic associations for the treatment of cancer, comprising an effective amount of a camptothecin, or a camptothecin derivative, with an effective amount of an alkylating agent such as a platin derivative, and methods of using such therapeutic associations.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: November 1, 2005
    Assignee: Aventis Pharma S.A.
    Inventor: Marie-Christine Bissery
  • Patent number: 6949582
    Abstract: A method of relieving analgesia and reducing inflammation using a cannabinoid delivery topical liniment composition containing from about 97.5% to about 99.5% by weight a 70% monohydric alcohol solution, and from about 0.5% to about 2.5% by weight of a synergistic cannabinoid mixture extracted from the female plant Cannabis sativa L, including in combination: 9-Tetrahydrocannabinol (delta-9-THC), 9-THC Propyl Analogue (THC-V), Cannabidiol (CBD), Cannabidiol Propyl Analogue (CBD-V), Cannabinol (CBN), Cannabichromene (CBC), Cannabichromene Propyl Analogue (CBC-V), Cannabigerol (CBG), terpenoids, and flavonoids. The liniment is applied topically, preferably by spraying, and the constituents of the mixture are absorbed through the skin and interact with cannabinoid receptors in the body and tissues of a human patient to produce therapeutic analgesic and anti-inflammatory effects without undesirable psychotropic side effects.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: September 27, 2005
    Inventor: Walter H. Wallace
  • Patent number: 6949558
    Abstract: The present invention provides a combination therapy for inhibiting the growth of tumor, for treating cancer, and for inducing cell death. The therapy comprises the sequential administration of taxane and a CDK1 antagonist. The present invention also provides pharmaceutical compositions comprising taxane and a CDK1 antagonist and kits comprising taxane and CDK1 antagonist.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: September 27, 2005
    Assignee: Yale University
    Inventors: Dario C. Altieri, Daniel S. O'Connor
  • Patent number: 6943187
    Abstract: This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using pyrrolidine derivatives.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: September 13, 2005
    Assignee: GPI Nil Holdings, Inc.
    Inventors: Joseph P. Steiner, Gregory S. Hamilton
  • Patent number: 6943192
    Abstract: Herein is disclosed a method of treating neoplastic disease, including cancer, comprising administering a pharmaceutical composition, the pharmaceutical composition comprising a highly concentrated aqueous solution of phenylacetylglutamine and phenylacetylisoglutamine in a 4:1 ratio, at an infusion rate of from 100 mL/hr to 400 mL/hr. In a further embodiment, herein is also disclosed a method of treating neoplastic disease, including cancer, comprising administering a pharmaceutical composition, the pharmaceutical composition comprising a highly concentrated aqueous solution of phenylacetate and (phenylacetylglutamine or phenylacetylisoglutamine) in a 4:1 ratio, at an infusion rate of from 100 mL/hr to 400 mL/hr. Herein are also disclosed the pharmaceutical compositions used in the above methods.
    Type: Grant
    Filed: May 22, 2001
    Date of Patent: September 13, 2005
    Inventor: Stanislaw R. Burzynski
  • Patent number: 6943166
    Abstract: The present invention relates to highly selective phosphodieterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3?,5?-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: September 13, 2005
    Assignee: Lilly ICOS LLC.
    Inventors: William Ernest Pullman, John Steven Whitaker
  • Patent number: 6943185
    Abstract: Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid (2-MTDC) and/or its physiologically tolerable salts for the treatment and/or prevention of cancer.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: September 13, 2005
    Assignee: Trommsdorff GmbH & Co. KG
    Inventors: Rudy Susilo, Hans Rommelspacher
  • Patent number: 6939893
    Abstract: The present invention discloses a method for enhancing the efficacy of anti-cancer agents. The method comprises administering to an individual, in need of such a treatment, an anti-cancer agent and a selenium compound. The selenium compounds may be administered before, during or after administration of the anti-cancer agent.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: September 6, 2005
    Assignee: Health Research, Inc.
    Inventors: Youcef M. Rustum, Shousong Cao, Farukh Durrani